Ipilimumab and nivolumab induced immune-related adverse events in metastatic mucosal melanoma

被引:1
|
作者
Cao, Yenong [1 ]
Afzal, Muhammad Zubair [2 ]
Shirai, Keisuke [2 ]
机构
[1] Dartmouth Hitchcock Med Ctr, Dept Internal Med, Lebanon, NH 03766 USA
[2] Dartmouth Hitchcock Med Ctr, Norris Cotton Canc Ctr, Lebanon, NH 03766 USA
关键词
skin cancer; unwanted effects; adverse reactions;
D O I
10.1136/bcr-2021-243713
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Mucosal melanoma is a rare subtype of melanoma and represents a unique diagnosis and treatment challenge. Immune-checkpoint inhibitors (ICIs) have revolutionised metastatic melanoma treatment, and one of the leading regimens is the combination of ipilimumab (anti-cytotoxic T lymphocyte-associated antigen 4: CTLA4) and nivolumab (anti-programmed cell death protein 1: PD1). We report a case of a patient with metastatic mucosal melanoma treated with ipilimumab and nivolumab who developed multiple immune-related adverse events (irAEs) including uveitis, type I diabetes complicated by diabetic ketoacidosis, destructive thyroiditis, hepatitis and vitiligo. Endocrinopathies including type 1 diabetes and hypothyroidism were treated with insulin and levothyroxine. Hepatitis was responsive to steroids. She had sustained complete response 12 months after discontinuation of the combination therapy. With the wide usage of ICIs in multiple types of malignancies, it is important for general practioners to recognise common and serious irAEs due to ICIs.
引用
收藏
页数:3
相关论文
共 50 条
  • [31] Genetic susceptibility to immune-related adverse events among melanoma patients treated with ipilimumab.
    Pluta, John
    Qian, Lu
    D'Andrea, Kurt
    Duan, Chunzhe
    Weathers, Benita
    Wind-Rotolo, Megan
    Kanetsky, Peter
    Nathanson, Katherine
    CANCER RESEARCH, 2021, 81 (13)
  • [32] Ipilimumab-induced gastrointestinal and hepatic immune-related adverse events: A national cohort
    Langbein, B.
    Labban, M.
    Chen, X.
    Reese, S.
    Lipsitz, S.
    McNabb-Baltar, J.
    Sun, M.
    Cole, A.
    Trinh, Q-D.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S948 - S948
  • [33] Interleukin-6 receptor blockade with tocilizumab to reduce immune-related toxicity with ipilimumab and nivolumab in metastatic melanoma
    Weber, Jeffrey S.
    Puranik, Amrutesh
    Mitzutani, Teruyuki
    Muramatsu, Tomoaki
    Goldberg, Judith D.
    Mehnert, Janice M.
    Li, Xiaochun
    Levinson, Benjamin A.
    Hamid, Omid
    Mehmi, Inderjit
    Faries, Mark B.
    Hodi, F. Stephen
    Buchbinder, Elizabeth Iannotti
    Ott, Patrick Alexander
    Bajwa, Sofia
    Arriola, Perla
    Legros, Naika
    Sullivan, Ryan J.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [34] Early tumour response assessment may avoid serious immune-related adverse events in nivolumab and ipilimumab combination therapy for stage IV melanoma
    Maeda, T.
    Hiura, A.
    Uehara, J.
    Toyoshima, R.
    Nakagawa, T.
    Yoshino, K.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (03) : 587 - 588
  • [35] Biomarkers Associated with Immune-Related Adverse Events under Checkpoint Inhibitors in Metastatic Melanoma
    Woelffer, Marcus
    Battke, Florian
    Schulze, Martin
    Feldhahn, Magdalena
    Flatz, Lukas
    Martus, Peter
    Forschner, Andrea
    CANCERS, 2022, 14 (02)
  • [36] Adverse events and estimated costs with the combination of ipilimumab and nivolumab in metastatic melanoma patients.
    Moura, Bianca Gautron
    Gerard, Camille Lea
    Testart, Nathalie
    Caikovsky, Marian
    Wicky, Alexandre M.
    Aedo-Lopez, Veronica
    Berthod, Gregoire
    Homicsko, Krisztian
    Prior, John
    Dromain, Clarisse
    Kandalaft, Lana E.
    Cuendet, Michel A.
    Michielin, Olivier
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [37] Immune-related adverse events (irAEs) with ipilimumab treatment of advanced melanoma: A single institution review.
    Myrdal, Caitlyn Nicole
    McBride, Ali
    Hsu, Chiu-Hsieh
    Sundararajan, Srinath
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [39] THE EFFECT OF CANNABIS CONSUMPTION ON IMMUNE RELATED ADVERSE EVENTS IN MELANOMA PATIENTS TREATED WITH IPILIMUMAB NIVOLUMAB COMBINATION THERAPY
    Silman, Yael Steinberg
    Eshet, Lia
    Kennett, Ron
    ben Ami, Sarah
    ONCOLOGY NURSING FORUM, 2021, 48 (02)